Hyperalgesic pain Signs and Symptoms Hyperalgesic pain
Conditions
Interventions
The effect of 40 mg methylphenidate and 2.5 mg lorazepam orally (p.o.) will be compared to placebo in a three-way cross-over design (placebo-methylphenidate-lorazepam). Sensory changes will be determi
Sponsors
Individual sponsor (Germany)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy volunteers of full age 2. Subject familiarized with the experimental procedure prior to experimentation and had given written informed consent 3. At least a 50% increase of pain to pinprick stimuli and a 25% increase of pain to electrical stimuli following high-frequency electrical stimulation in a screening visit
Exclusion criteria
Exclusion criteria: 1. Skin lesions at the test and/or control site 2. Use of any medication within one day prior to study onset except contraceptives 3. Known hypersensitivity to histamine or methylphenidate and lorazepam and their derivates 4. Any history of allergy or drug hypersensitivity 5. Chronic use of analgesics or Central Nervous System (CNS) active drugs 6. Pregnancy or nursing 7. Any acute or chronic disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following outcomes will be assessed based on the sensory changes determined by QST during the intervention: 1. Spread of the area of dynamic allodynia and static hyperalgesia 2. Combined analgesic and anti-hyperalgesic effect to mechanical and electrical stimuli on the site of conditioning stimulation | — |
Secondary
| Measure | Time frame |
|---|---|
| The following outcomes will be assessed based on the sensory changes determined by QST during the intervention: 1. Anti-hyperalgesic effect to electrical and mechanical test stimuli 2. Analgesic effect to electrical and mechanical test stimuli 3. Anti-wind up pain, tested by mechanical pinprick stimuli | — |
Countries
Germany
Outcome results
None listed